Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors

NCT07330895 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT07330895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07330895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2025
Completion date
December 31, 2027
Enrollment
19 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cd19+ relapse/refractory b-all